Literature DB >> 18022045

Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use.

Seth Himelhoch1, Geetanjali Chander, John A Fleishman, James Hellinger, Paul Gaist, Kelly A Gebo.   

Abstract

OBJECTIVE: Among HIV-infected individuals, we examined whether having co-occurring serious mental illness (SMI) and injection drug use (IDU) impacts: (a) receipt of highly active antiretroviral therapy (HAART), and (b) utilization of inpatient HIV services, compared to those who have SMI only, IDU only or neither SMI nor IDU.
METHOD: Demographic, clinical and resource utilization data were collected from medical records of 5119 patients in HIV primary care at four US HIV care sites in different geographic regions with on-site mental health services in 2001. We analyzed receipt of HAART using multivariate logistic regression and the number of medical hospital admissions using multivariate logistic and Poisson regression analyses, which controlled for demographic factors, receipt of HAART, CD4 count and HIV-1 RNA.
RESULTS: Those with co-occurring SMI and IDU [adjusted odds ratio (AOR)=0.52; 95% confidence interval (95% CI)=0.41-0.81] and those with IDU alone (AOR=0.64; 95% CI=0.58-0.85) were significantly less likely to receive HAART than those with neither SMI nor IDU, controlling for demographic and clinical factors. Those with co-occurring SMI and IDU were more likely to use any inpatient medical services (AOR=2.22; 95% CI=1.64-3.01) and were significantly more likely to use them more frequently (incidence rate ratio=1.33; 95% CI=1.13-1.55) than those with neither SMI nor IDU, SMI only or IDU only.
CONCLUSION: HIV-infected individuals with co-occurring SMI and IDU are significantly more likely to utilize HIV-related medical inpatient services than individuals with no comorbidity or with only one comorbidity. Individuals with both SMI and IDU did not differ from those with IDU only in receipt of HAART. Inpatient hospitalizations are expensive, and efforts should be targeted towards these populations to reduce potentially avoidable inpatient care.

Entities:  

Mesh:

Year:  2007        PMID: 18022045      PMCID: PMC2629392          DOI: 10.1016/j.genhosppsych.2007.03.008

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  46 in total

1.  The treatment of unrelated disorders in patients with chronic medical diseases.

Authors:  D A Redelmeier; S H Tan; G L Booth
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

2.  Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study.

Authors:  M F Shapiro; S C Morton; D F McCaffrey; J W Senterfitt; J A Fleishman; J F Perlman; L A Athey; J W Keesey; D P Goldman; S H Berry; S A Bozzette
Journal:  JAMA       Date:  1999 Jun 23-30       Impact factor: 56.272

3.  Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.

Authors:  S Bassetti; M Battegay; H Furrer; M Rickenbach; M Flepp; L Kaiser; A Telenti; P L Vernazza; E Bernasconi; P Sudre
Journal:  J Acquir Immune Defic Syndr       Date:  1999-06-01       Impact factor: 3.731

Review 4.  HIV seroprevalence among people with severe mental illness in the United States: a critical review.

Authors:  F Cournos; K McKinnon
Journal:  Clin Psychol Rev       Date:  1997

Review 5.  HIV and people with serious mental illness: the public sector's role in reducing HIV risk and improving care.

Authors:  G Sullivan; P Koegel; D E Kanouse; F Cournos; K McKinnon; A S Young; D Bean
Journal:  Psychiatr Serv       Date:  1999-05       Impact factor: 3.084

Review 6.  Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.

Authors:  L Dixon
Journal:  Schizophr Res       Date:  1999-03-01       Impact factor: 4.939

7.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

8.  Delays in protease inhibitor use in clinical practice.

Authors:  K M Fairfield; H Libman; R B Davis; D M Eisenberg
Journal:  J Gen Intern Med       Date:  1999-07       Impact factor: 5.128

9.  A randomized trial of assertive community treatment for homeless persons with severe mental illness.

Authors:  A F Lehman; L B Dixon; E Kernan; B R DeForge; L T Postrado
Journal:  Arch Gen Psychiatry       Date:  1997-11

10.  Use of hospital services by AIDS patients with psychiatric illness.

Authors:  K K Uldall; L A Koutsky; D H Bradshaw; M Krone
Journal:  Gen Hosp Psychiatry       Date:  1998-09       Impact factor: 3.238

View more
  17 in total

Review 1.  Quality of medical care for persons with serious mental illness: A comprehensive review.

Authors:  Emma E McGinty; Julia Baller; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  Schizophr Res       Date:  2015-04-27       Impact factor: 4.939

2.  Half of 30-Day Hospital Readmissions Among HIV-Infected Patients Are Potentially Preventable.

Authors:  Ank E Nijhawan; Ellen Kitchell; Sarah Shelby Etherton; Piper Duarte; Ethan A Halm; Mamta K Jain
Journal:  AIDS Patient Care STDS       Date:  2015-07-08       Impact factor: 5.078

3.  Do Symptoms of Depression Interact with Substance Use to Affect HIV Continuum of Care Outcomes?

Authors:  Anthony T Fojo; Catherine R Lesko; Keri L Calkins; Richard D Moore; Mary E McCaul; Heidi E Hutton; William C Mathews; Heidi Crane; Katerina Christopoulos; Karen Cropsey; Michael J Mugavero; Kenneth Mayer; Brian W Pence; Bryan Lau; Geetanjali Chander
Journal:  AIDS Behav       Date:  2019-03

4.  The impact of an HIV/AIDS adult integrated health program on leaving hospital against medical advice among HIV-positive people who use illicit drugs.

Authors:  Lianping Ti; M-J Milloy; Rosalind Baltzer Turje; Julio Montaner; Evan Wood; Thomas Kerr
Journal:  J Public Health (Oxf)       Date:  2017-06-01       Impact factor: 2.341

5.  Is serious mental illness associated with earlier death among persons with HIV? Ten year follow up in Maryland Medicaid Recipients.

Authors:  Geetanjali Chander; YiYi Zhang; Susan dosReis; Donald M Steinwachs; Daniel E Ford; Eliseo Guallar; Gail Daumit
Journal:  J AIDS HIV Res       Date:  2012-08

6.  High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.

Authors:  Tara Perti; Misty Saracino; Jared M Baeten; Christine Johnston; Kurt Diem; Negusse Ocbamichael; Meei-Li Huang; Stacy Selke; Amalia Magaret; Lawrence Corey; Anna Wald
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

7.  HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.

Authors:  Geetanjali Chander; Seth Himelhoch; John A Fleishman; James Hellinger; Paul Gaist; Richard D Moore; Kelly A Gebo
Journal:  AIDS Care       Date:  2009-05

8.  Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings.

Authors:  R Douglas Bruce
Journal:  Int J Drug Policy       Date:  2010-03

9.  HIV patients with psychiatric disorders are less likely to discontinue HAART.

Authors:  Seth Himelhoch; Clayton H Brown; James Walkup; Geetanjali Chander; P Todd Korthius; Joseph Afful; Kelly A Gebo
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

10.  Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy.

Authors:  Lisa R Metsch; Christine Bell; Margaret Pereyra; Gabriel Cardenas; Tanisha Sullivan; Allan Rodriguez; Lauren Gooden; Nayla Khoury; Tamy Kuper; Toye Brewer; Carlos del Rio
Journal:  Am J Public Health       Date:  2009-04-16       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.